CD19-CAR-T in B-cell Malignancies Patients

Status Completed

Clinical Trial Summary

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-CAR-T cells in patients with refractory and relapsed B-cell malignancies.

Clinical Trial Description

This Phase I study is designed as a pilot trial evaluating the safety and of CD19-CAR-T cell therapy in subjects with refractory and relapsed B cell malignancies. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19-CAR-T cells. Safety and efficacy of CD19-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19-CAR-T cells therapy in patients with refractory and relapsed B-cell malignancies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03952923
Study type	Interventional
Source	Hebei Yanda Ludaopei Hospital
Contact
Status	Completed
Phase	Phase 1
Start date	August 1, 2019
Completion date	March 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Recruiting	`NCT05106907` - Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma	Phase 1
Recruiting	`NCT05106946` - Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma	Phase 1
Recruiting	`NCT05294731` - Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader	Phase 1/Phase 2
Recruiting	`NCT05643742` - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT04035434` - A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	Phase 1/Phase 2
Recruiting	`NCT05602363` - AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT03559439` - CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies	Phase 1